Lineage Cell Therapeutics, Inc. (LCTX) is a clinical-stage company that focuses its drugs on allogeneic cell therapies. This centers their pipeline around therapies that utilize engineered cells used to replace or repair damaged tissue
Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical Risk
Summary
- Lineage Cell Therapeutics is rated Hold due to its reliance on out-licensing and a risk-adjusted fair value below the current share price.
- LCTX’s valuation hinges on OpRegen’s clinical success, with pivotal Phase 2a readouts expected by late 2026 or early-to-mid 2027.
- Strategic partnerships reduce dilution and cash burn, providing an operational runway into Q3 2028 with $50.8 million in cash.
- Risks include dependence on partners for development, potential trial failures, and limited control over clinical and commercialization timelines.
This article was written by
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.